Effect of Ranolazine Monotherapy on Glycemic Control in Subjects With Type 2 Diabetes

OBJECTIVE: Ranolazine is an antianginal drug that mediates its effects by inhibition of cardiac late sodium current. Although ranolazine is not approved for the treatment of type 2 diabetes, in post hoc analyses of pivotal angina trials, ranolazine was associated with reductions in percent glycosyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckel, Robert H., Henry, Robert R., Yue, Patrick, Dhalla, Arvinder, Wong, Pamela, Jochelson, Philip, Belardinelli, Luiz, Skyler, Jay S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2015
Materias:
Diabetes Care Symposium
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477340/
https://www.ncbi.nlm.nih.gov/pubmed/26049552
http://dx.doi.org/10.2337/dc14-2629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477340/
https://www.ncbi.nlm.nih.gov/pubmed/26049552
http://dx.doi.org/10.2337/dc14-2629

Ejemplares similares